Overview

Concomitant Chemoradiotherapy With Weekly Paclitaxel and Vinorelbine and Granulocyte Colony Stimulating Factor (GCSF) Support in Patients With Advanced Breast Cancer

Status:
Completed

Trial end date:
2012-11-01

Target enrollment:

Participant gender:

Summary

The goal of this study is to determine the feasibility based on toxicity and response rate of giving paclitaxel weekly with concomitant every-other week radiotherapy to limit skin toxicity. This study will also seek to determine the maximally tolerated dose of Navelbine added to this combination when followed by Filgrastim and the dose-limiting toxicities of this regimen.

Phase:

Phase 1

Details

Lead Sponsor:

University of Chicago

Collaborator:

Amgen

Treatments:

Albumin-Bound Paclitaxel
Lenograstim
Paclitaxel
Vinblastine
Vinorelbine